The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Somatic mutations affect key pathways in lung adenocarcinoma
Open accessAbstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While gain of 7p and loss of 8p have been previously reported to occur specifically in EGFR mutated adenocarcinomas16, 17, gain of 16p was a novel association.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [22]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [60]
In the citing paper
“Similarly, mutations in ERBB4 were identified in cancer, particularly melanoma (Prickett et al., 2009), lung adenocarcinoma (Ding et al., 2008), and medulloblastoma (Gilbertson et al., 2001).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ding et al., 2008
In the citing paper
“Gain/amplification of the mutant EGFR allele has previously been reported to frequently occur in LAC and is known to drive tumor progression17.”
From Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Flagged first, then by citations
2 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,007
Non-Random Integration of the HPV Genome in Cervical Cancer
Schmitz, M., Driesch, C., Jansen, L., Runnebaum, I. B., & Dürst, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039632 · Cited by 129
Myc Is a Metastasis Gene for Non-Small-Cell Lung Cancer
Rapp, U. R., Korn, C. B., Ceteci, F., Karreman, C., Luetkenhaus, K., Serafin, V., Zanucco, E., Castro, I. C., & Potapenko, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006029 · Cited by 132
Insertions and Deletions Target Lineage-Defining Genes in Human Cancers
Imielinski, M. B., Guo, G., & Meyerson, M. M. (2017) · Cell · doi:10.1016/j.cell.2016.12.025 · Cited by 131
Self-citationYoon, Y., Kim, H., Han, S., Oh, D. Y., Im, S., Bang, Y., & Kim, T. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20607 · Cited by 129
Hsu, K.-H., Ho, C., Hsia, T., Tseng, J., Su, K., Wu, M., Chiu, K.-L., Yang, T., Chen, K.-C., Ooi, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120852 · Cited by 127
Self-citationWilliamson, C. T., Kubota, E., Hamill, J. D., Klimowicz, A. C., Ye, R., Muzik, H., Dean, M. L., Tu, L., Gilley, D. P., Magliocco, A. M., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200229 · Cited by 131
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Nguyen‐Ngoc, T., Bouchaab, H., Adjei, A. A., & Peters, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000644 · Cited by 135
Mahoney, C., Choudhury, B., Davies, H. R., Edkins, S., Greenman, C., van Haaften, G. W., Mironenko, T., Santarius, T., Stevens, C., Stratton, M. R., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604886 · Cited by 128
Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC
Amato, K. R., Wang, S., Hastings, A. K., Youngblood, V., Santapuram, P. R., Chen, H., Cates, J., Colvin, D. C., Ye, F., Brantley‐Sieders, D. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72522 · Cited by 129
Lipoprotein receptors – an evolutionarily ancient multifunctional receptor family
Dieckmann, M., Dietrich, M. F., & Herz, J. (2010) · Biological Chemistry · doi:10.1515/bc.2010.129 · Cited by 135
The Biological Role of PI3K Pathway in Lung Cancer
Sarris, E., Saif, M. W., & Syrigos, K. (2012) · Pharmaceuticals · doi:10.3390/ph5111236 · Cited by 128
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer
Schabath, M. B., Cress, W. D., & Muñoz-Antonia, T. (2016) · Cancer Control · doi:10.1177/107327481602300405 · Cited by 127
Molecular Pathology of Primary Non-small Cell Lung Cancer
Suster, D. I., & Mino-Kenudson, M. A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.08.004 · Cited by 130
Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer
Gill, R. K., Yang, S.-H., Meerzaman, D. M., Mechanic, L. E., Bowman, E. D., Jeon, H.-S., Roy‐Chowdhuri, S., Shakoori, A., Dracheva, T., Hong, K.-M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.98 · Cited by 125
Aguilera, K. Y., Huang, H., Du, W., Hagopian, M. M., Wang, Z., Hinz, S., Hwang, T. H., Wang, H., Fleming, J. B., Castrillon, D. H., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0834 · Cited by 118
“Dasatinib in particular has demonstrated promising therapeutic efficacy in lung cancer cells (57) and squamous cell carcinoma patients (58) harboring gain-of-function DDR2 mutations.”
BackgroundReungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 127
The mutational landscape of chromatin regulatory factors across 4,623 tumor samples
González-Pérez, A., Jené-Sanz, A., & López-Bigas, N. (2013) · Genome biology · doi:10.1186/gb-2013-14-9-r106 · Cited by 131
Targeting the fibroblast growth factor receptor family in cancer
Hallinan, N., Finn, S. P., Cuffe, S. D., Rafee, S., O'Byrne, K. J., & Gately, K. A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.015 · Cited by 125
Hensing, T. A., Chawla, A., Batra, R., & Salgia, R. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8778-4_5 · Cited by 127
Targeting mutant fibroblast growth factor receptors in cancer
Greulich, H. E., & Pollock, P. M. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.012 · Cited by 128
Self-citationMorris, M. K., Sáez-Rodríguez, J., Clarke, D. C., Sorger, P. K., & Lauffenburger, D. A. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001099 · Cited by 123
Kubota, E., Williamson, C. T., Ye, R., Elegbede, A. A., Peterson, L., Lees‐Miller, S. P., & Bebb, D. G. (2014) · Cell Cycle · doi:10.4161/cc.29212 · Cited by 125
Curcumin Induces Autophagy via Activating the AMPK Signaling Pathway in Lung Adenocarcinoma Cells
Xiao, K., Jiang, J., Guan, C., Dong, C., Wang, G., Bai, L., Sun, J., Hu, C., & Bai, C. (2013) · Journal of Pharmacological Sciences · doi:10.1254/jphs.13085fp · Cited by 125
Samadian, H., Salami, M. S., Jaymand, M., Azarnezhad, A., Najafi, M., Barabadi, H., & Ahmadi, A. (2020) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2020.108296 · Cited by 127
Garner, A. P., Bialucha, C. U., Sprague, E. R., Garrett, J. T., Sheng, Q., Li, S., Sineshchekova, O., Saxena, P., Sutton, C. R., Chen, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1198 · Cited by 125
How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Politi, K. A., & Pao, W. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 126
Self-citationState of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine
Nishino, M., Hatabu, H., Johnson, B. E., & McLoud, T. C. (2014) · Radiology · doi:10.1148/radiol.14122524 · Cited by 124
Self-citationGenomic and proteomic biomarkers for cancer: A multitude of opportunities
Tainsky, M. A. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.04.004 · Cited by 124
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
Imielinski, M. B., Greulich, H. E., Kaplan, B., Araujo, L. H., Amann, J. M., Horn, L., Schiller, J. H., Villalona-Calero, M. A., Meyerson, M. M., & Carbone, D. P. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72763 · Cited by 122
Self-citationTucker, J. A., Klein, T., Breed, J., Breeze, A. L., Overman, R., Phillips, C., & Norman, R. A. (2014) · Structure · doi:10.1016/j.str.2014.09.019 · Cited by 124
Sholl, L. M., Yeap, B. Y., Iafrate, A. J., Tisch, A. H., Chou, Y.-P., Wu, M., Goan, Y., Su, L., Benedettini, E., Yu, J. Q., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2477 · Cited by 122
Self-citationGoodwin, J. M., Svensson, R. U., Lou, H. J., Winslow, M. M., Turk, B. E., & Shaw, R. J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.06.021 · Cited by 123
Buettner, R., Wolf, J., & Thomas, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9867 · Cited by 123
Self-citationYAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting
Sardo, F. L., Strano, S., & Blandino, G. (2018) · Cancers · doi:10.3390/cancers10050137 · Cited by 124
The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R
Zhong, D., Xiong, L., Liu, T., Liu, X., Liu, X., Chen, J., Sun, S., Khuri, F. R., Zong, Y., Zhou, Q., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.005280 · Cited by 126
Targeting DNA repair mechanisms in cancer
Furgason, J. M., & Bahassi, E. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.10.009 · Cited by 122
Looyenga, B. D., Hutchings, D., Cherni, I., Kingsley, C., Weiss, G. J., & MacKeigan, J. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030820 · Cited by 120
Translating cancer ‘omics’ to improved outcomes: Figure 1.Preprint
Vucic, E. A., Thu, K. L., Robison, K. E., Rybaczyk, L. A., Chari, R., Alvarez, C. E., & Lam, W. L. (2012) · Genome Research · doi:10.1101/gr.124354.111 · Cited by 124
Calles, A., Sholl, L. M., Rodig, S. J., Pelton, A. K., Hornick, J. L., Butaney, M., Lydon, C., Dahlberg, S. E., Oxnard, G. R., Jackman, D. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3112 · Cited by 115
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
Samuel, N., & Hudson, T. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.215 · Cited by 117
Fraser, M. E., Berlín, A., Bristow, R. G., & van der Kwast, T. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.10.020 · Cited by 123
DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer
Moncho-Amor, V., de Cáceres, I. I., Bandrés, E., Martı́nez-Poveda, B., Orgaz, J. L., Sánchez‐Pérez, I., Zazo, S., Rovira, A., Albanell, J., Jiménez, B., et al. (2010) · Oncogene · doi:10.1038/onc.2010.449 · Cited by 122
RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas
Konstantinidou, G., Ramadori, G., Torti, F., Kangasniemi, K., Ramirez, R. E., Cai, Y., Behrens, C., Dellinger, M. T., Brekken, R. A., Wistuba, I. I., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0388 · Cited by 114
Self-citationIdentification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
Majewski, I. J., Mittempergher, L., Davidson, N., Bosma, A. R., Willems, S. M., Horlings, H. M., de Rink, I., Greger, L., Hooijer, G. K. J., Peters, D. D. G. C., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4209 · Cited by 118
Pan-Cancer Analysis of Mutation Hotspots in Protein Domains
Miller, M. L., Reznik, E., Gauthier, N. P., Aksoy, B. A., Korkut, A., Gao, J., Ciriello, G., Schultz, N. D., & Sander, C. (2015) · Cell Systems · doi:10.1016/j.cels.2015.08.014 · Cited by 121
The genetics and biology of KRAS in lung cancer
Westcott, P. M. K., & To, M. D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10098 · Cited by 116
DEGAS: De Novo Discovery of Dysregulated Pathways in Human Diseases
Ulitsky, I., Krishnamurthy, A., Karp, R. M., & Ron Shamir, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013367 · Cited by 116
Cancer Missense Mutations Alter Binding Properties of Proteins and Their Interaction Networks
Nishi, H., Tyagi, M. G., Teng, S., Shoemaker, B. A., Hashimoto, K., Alexov, E. G., Wuchty, S., & Panchenko, A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066273 · Cited by 117
Selamat, S. A., Galler, J. S., Joshi, A. D., Fyfe, M. N., Campan, M., Siegmund, K. D., Kerr, K. M., & Laird‐Offringa, I. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021443 · Cited by 117
Molecular Pathology of Non–Small Cell Lung Cancer
Aisner, D. L., & Marshall, C. B. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpfr12wjkceezz · Cited by 119
Scarfò, I., Pellegrino, E., Mereu, E., Kwee, I., Agnelli, L., Bergaggio, E., Garaffo, G., Vitale, N., Caputo, M., Machiorlatti, R., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614503 · Cited by 116
Wang, C., Yin, R. H., Dai, J., Gu, Y., Cui, S., Ma, H., Zhang, Z., Huang, J., Qin, N., Jiang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04492-2 · Cited by 115
Self-citationTargeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Rothschild, S. I. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 117
Sholl, L. M., Xiao, Y., Joshi, V. A., Yeap, B. Y., Cioffredi, L., Jackman, D. M., Lee, C., Janne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 116
Jia, P., & Zhao, Z. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003460 · Cited by 114
Signaling cross-talk in the resistance to HER family receptor targeted therapy
Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 118
Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma
Pò, A., Silvano, M., Miele, E., Capalbo, C., Eramo, A., Salvati, V., Todaro, M., Besharat, Z. M., Catanzaro, G., Cucchi, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.91 · Cited by 114
Exploiting synthetic lethal interactions for targeted cancer therapy
Reinhardt, H. C., Jiang, H., Hemann, M. T., & Yaffe, M. B. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9626 · Cited by 110
Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature
Haninger, D. M., Kloecker, G. H., Bousamra, M., Nowacki, M. R., & Slone, S. P. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.170 · Cited by 113
Human genetics and genomics a decade after the release of the draft sequence of the human genome
Naidoo, N., Yudi Pawitan, Y., Soong, R., Cooper, D. N., & Ku, C. (2011) · Human Genomics · doi:10.1186/1479-7364-5-6-577 · Cited by 117
Neoplasms Associated with Germline and Somatic NF1 Gene Mutations
Patil, S., & Chamberlain, R. S. (2012) · The Oncologist · doi:10.1634/theoncologist.2010-0181 · Cited by 116
Chu, D., & Wei, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5572-x · Cited by 112
Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma
Girard, N., Sima, C. S., Jackman, D. M., Sequist, L. V. D., Chen, H., Yang, J. C., Ji, H., Waltman, B. A., Rosell, R., Tarón, M., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00010111 · Cited by 113
Self-citationIntegrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas
Welander, J., Larsson, C., Bäckdahl, M., Hareni, N., Sivlér, T., Brauckhoff, M., Söderkvist, P., & Gimm, O. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds402 · Cited by 112
Alam, M., Alam, S., Shamsi, A., Adnan, M., Elasbali, A. M., Al‐Soud, W. A., Alreshidi, M. M., Hawsawi, Y. M., Tippana, A., Pasupuleti, V. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869672 · Cited by 122
Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells
Zhou, J., Huang, W., Tao, R., Ibaragi, S., Lan, F., Ido, Y., Wu, X., Alekseyev, Y. O., Lenburg, M. E., Hu, G.-F., et al. (2009) · Oncogene · doi:10.1038/onc.2009.63 · Cited by 116
Identification of rare cancer driver mutations by network reconstructionPreprint
Torkamani, A., & Schork, N. J. (2009) · Genome Research · doi:10.1101/gr.092833.109 · Cited by 115
Bidkhori, G., Narimani, Z., Ashtiani, S. H., Moeini, A., Nowzari-Dalini, A., & Masoudi‐Nejad, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067552 · Cited by 111
Noskovičová, N., Petřek, M., Eickelberg, O., & Heinzelmann, K. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0294tr · Cited by 120
Segers, V. F. M., Dugaucquier, L., Feyen, E., Shakeri, H., & Keulenaer, G. W. D. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00499-4 · Cited by 112
Sitthideatphaiboon, P., Galán‐Cobo, A., Negrao, M. V., Qu, X. H., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2859 · Cited by 115
Self-citationThe Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to ClinicPreprint
Mardis, E. R. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036269 · Cited by 118
Self-citationHsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro
Sun, Y., Fang, R., Li, C., Li, L., Li, F., Ye, X., & Chen, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.127 · Cited by 110
Suzuki, A., Makinoshima, H., Wakaguri, H., Esumi, H., Sugano, S., Kohno, T., Tsuchihara, K., & Suzuki, Y. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku885 · Cited by 109
Freidin, M. B., Freydin, M., Leung, M., Montero, Á., Nicholson, A. G., & Lim, E. K. S. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.242453 · Cited by 110
Enrichment of sequencing targets from the human genome by solution hybridization
Tewhey, R., Nakano, M., Wang, X., Pabón-Peña, C., Novak, B. A., Giuffre, A. C., Lin, E., Happe, S., Roberts, D. N., LeProust, E. M., et al. (2009) · Genome biology · doi:10.1186/gb-2009-10-10-r116 · Cited by 119
Wang, Y., Tian, Y., Morley, M. P., Lu, M. M., DeMayo, F. J., Olson, E. N., & Morrisey, E. E. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.01.012 · Cited by 111
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
Li, S., Choi, Y., Gong, Z., Liu, X., Lira, M. E., Kan, Z., Oh, E., Wang, J., Ting, J. C., Ye, X. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.142 · Cited by 114
Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma
Çeliktaş, M., Tanaka, I., Tripathi, S. C., Fahrmann, J. F., Aguilar-Bonavides, C., Villalobos, P. A., Delgado, O., Dhillon, D. S., Dennison, J. B., Ostrin, E. J., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw231 · Cited by 110
Facchinetti, F., Bluthgen, M. V., Tergemina-Clain, G., Faivre, L., Pignon, J., Planchard, D., Remón, J., Soria, J., Lacroix, L., & Besse, B. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.002 · Cited by 109
Tam, K. W., Zhang, W., Soh, J., Stastny, V., Chen, M., Sun, H., Thu, K., Rios, J. J., Yang, C., Marconett, C. N., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a46c0c · Cited by 109
Lung Cancer: Are we up to the Challenge?
Esposito, L., Conti, D., Ailavajhala, R., Khalil, N., & Giordano, A. (2010) · Current Genomics · doi:10.2174/138920210793175903 · Cited by 110
Wu, K., Zhang, X., Li, F., Xiao, D., Hou, Y., Zhu, S., Liu, D., Ye, X., Ye, M., Yang, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms10131 · Cited by 109
Self-citationCowin, P. A., George, J., Fereday, S., Loehrer, E. A., Loo, P. V., Cullinane, C. M., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M. S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0203 · Cited by 109
DNA damage response and prostate cancer: defects, regulation and therapeutic implications
Karanika, S., Karantanos, T., Li, L., Corn, P. G., & Thompson, T. C. (2014) · Oncogene · doi:10.1038/onc.2014.238 · Cited by 111
EphA receptor signaling—Complexity and emerging themes
Miao, H., & Wang, B. (2011) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2011.10.013 · Cited by 108
Notch3 Functions as a Tumor Suppressor by Controlling Cellular Senescence
Cui, H., Kong, Y., Xu, M., & Zhang, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3902 · Cited by 106
High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families
Helgadóttir, H., Höiom, V., Jönsson, G. B., Tuominen, R., Ingvar, C., Borg, Å., Olsson, H. L., & Hansson, J. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102320 · Cited by 112
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Heist, R. S., Shim, H. S., Gingipally, S., Mino-Kenudson, M. A., Le, L. P., Gainor, J. F., Zheng, Z., Aryee, M. J., Xia, J., Jia, P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0510 · Cited by 111
Self-citationTP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
Halvorsen, A. R., Silwal‐Pandit, L., Meza‐Zepeda, L. A., Vodák, D., Vu, P., Sagerup, C., Hovig, E. J., Myklebost, O., Børresen‐Dale, A., Brustugun, O. T., et al. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00085 · Cited by 109
Malone, C. F., Emerson, C. E., Ingraham, R., Barbosa, W. A., Guerra, S. L., Yoon, H., Liu, L. L., Michor, F., Haigis, M. C., Macleod, K. F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0177 · Cited by 108
An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness
Liu, L., Tao, T., Liu, S., Yang, X., Chen, X., Liang, J., Hong, R., Wang, W., Yang, Y., Li, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22971-x · Cited by 107
Yue, D., Liu, W., Chen, C., Zhang, T., Ma, Y., Cui, L., Gu, Y., Bei, T., Zhao, X., Zhang, B., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-106 · Cited by 109
Self-citationA Genomic Strategy to Elucidate Modules of Oncogenic Pathway Signaling Networks
Chang, J. T., Carvalho, C. M., Mori, S., Bild, A. H., Gatza, M. L., Wang, Q., Lucas, J. E., Potti, A., Febbo, P. G., West, M., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.030 · Cited by 107
ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma
Schmitt, A., Knittel, G., Welcker, D., Yang, T.-P., George, J., Nowak, M., Leeser, U., Büttner, R., Perner, S., Peifer, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3398 · Cited by 109
Shi, Y., Lei, Y., Liu, L., Zhang, S., Wang, W., Zhao, J., Zhao, S., Dong, X., Yao, M., Wang, K., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3649 · Cited by 110
Chronic cadmium exposure in vitro induces cancer cell characteristics in human lung cells
Person, R. J., Tokar, E. J., Xu, Y., Orihuela, R., Ngalame, N. N. O., & Waalkes, M. P. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.06.013 · Cited by 106
Our changing view of the genomic landscape of cancer
Bell, D. W. (2009) · The Journal of Pathology · doi:10.1002/path.2645 · Cited by 109
The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer
Elkamhawy, A., Lu, Q., Nada, H., Woo, J., Quan, G., & Lee, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126535 · Cited by 104
Metadata
- Authors
- Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., Fulton, L., Fulton, R. S., Zhang, Q., Wendl, M. C., Lawrence, M. S., Larson, D. E., Chen, K., Dooling, D. J., Sabo, A., Hawes, A. C., Shen, H., Jhangiani, S. N., Lewis, L. R., Hall, O., Zhu, Y., Mathew, T., Ren, Y., Yao, J., Scherer, S. E., Clerc, K., Metcalf, G. A., Ng, B., Milosavljevic, A., Gonzalez-Garay, M. L., Osborne, J. R., Meyer, R., Shi, X., Tang, Y., Koboldt, D. C., Lin, L., Abbott, R., Miner, T. L., Pohl, C., Fewell, G., Haipek, C., Schmidt, H., Dunford-Shore, B. H., Kraja, A., Crosby, S. D., Sawyer, C. S., Vickery, T., Sander, S., Robinson, J., Winckler, W., Baldwin, J., Chirieac, L. R., Dutt, A., Fennell, T., Hanna, M., Johnson, B. E., Onofrio, R. C., Thomas, R. K., Tonon, G., Weir, B. A., Zhao, X., Ziaugra, L., Zody, M. C., Giordano, T., Orringer, M. B., Roth, J. A., Spitz, M. R., Wistuba, I. I., Ozenberger, B., Good, P. J., Chang, A. C., Beer, D. G., Watson, M. A., Ladanyi, M., Broderick, S., Yoshizawa, A., Travis, W. D., Pao, W., Province, M. A., Weinstock, G. M., Varmus, H. E., Gabriel, S. B., Lander, E. S., Gibbs, R. A., Meyerson, M., & Wilson, R. K.
- Affiliations
- Washington University in St. Louis (US)
- Broad Institute (US)
- Baylor College of Medicine (US)
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Max Planck Society (DE)
- University of Michigan (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Institutes of Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Meyerson, Matthew
- Wilson, Richard K.
- ORCID
- Ding, Li
- Getz, Gad
- Wheeler, David A.
- Mardis, Elaine R.
- McLellan, Michael D.
- Cibulskis, Kristian
- Greulich, Heidi
- Muzny, Donna M.
- Morgan, Margaret B.
- Fulton, Lucinda
- Fulton, Robert S.
- Wendl, Michael C.
- Lawrence, Michael S.
- Larson, David E.
- Chen, Ken
- Sabo, Aniko
- Shen, Hua
- Jhangiani, Shalini N.
- Zhu, Yiming
- Ren, Yanru
- Yao, Jiqiang
- Scherer, Steven E.
- Metcalf, Ginger A.
- Ng, Brian
- Milosavljevic, Aleksandar
- Tang, Yuzhu
- Koboldt, Daniel C.
- Lin, Ling
- Pohl, Craig
- Crosby, Seth D.
- Vickery, Tammi
- Winckler, Wendy
- Chirieac, Lucian R.
- Dutt, Amit
- Fennell, Tim
- Johnson, Bruce E.
- Thomas, Roman K.
- Tonon, Giovanni
- Zody, Michael C.
- Giordano, Thomas
- Roth, Jack A.
- Wistuba, Ignacio I.
- Ozenberger, Bradley
- Chang, Andrew C.
- Beer, David G.
- Watson, Mark A.
- Ladanyi, Marc
- Broderick, Stephen
- Yoshizawa, Akihiko
- Travis, William D.
- Pao, William
- Province, Michael A.
- Weinstock, George M.
- Varmus, Harold E.
- Gabriel, Stacey B.
- Lander, Eric S.
- Gibbs, Richard A.
- Meyerson, Matthew
- Wilson, Richard K.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7216
- Pages
- 1069-1075
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2694412
- OpenAlex
- W2163798887
- Cited by
- 2,681
- References
- 54
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 53 · 2023: 122 · 2022: 124 · 2021: 149 · 2020: 147 · 2019: 145 · 2018: 121 · 2017: 141 · 2016: 158 · 2015: 206 · 2014: 254 · 2013: 213 · 2012: 227
- FWCI
- 167.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Broad Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U19CA084953, P50CA070907, R01CA154365)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, carcinogenesis, tyrosine kinase, EphA3, Eph receptors, KDR, NTRK, tumor suppressor, neurofibromatosis type 1, APC, RB1, ATM, PTPRD, LRP1B, smoking, DNA repair deficiency, signaling pathways, molecular targets, mutational landscape
- MeSH terms
- Adenocarcinoma, Bronchiolo-Alveolar, Female, Humans, Lung Neoplasms, Male, Mutation, Proto-Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Gene Dosage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
